---
title: "Plasma P-tau217, NfL and GFAP Predict Cognitive and Functional Decline in Early Sporadic Parkinson"
id: "medrxiv-1-plasma-neurodegeneration-biomarkers-and-clinical-progression-in-early-sporadic"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-1-plasma-neurodegeneration-biomarkers-and-clinical-progression-in-early-sporadic"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.18.26368420v1?rss=1"
published_at: "2026-11-20T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Plasma P-tau217, NfL and GFAP Predict Cognitive and Functional Decline in Early Sporadic Parkinson
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-1-plasma-neurodegeneration-biomarkers-and-clinical-progression-in-early-sporadic
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.18.26368420v1?rss=1)
- **Published At:** 2026-11-20T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators analyzed baseline plasma biomarkers in deeply phenotyped participants from the Parkinson's Precision Medicine Initiative (PPMI). - The cohort included 523 early (<2 years since diagnosis) sporadic **Parkinson's disease** (PD) participants with positive CSF **aSyn-SAA** and 97 healthy controls (HC) with negative aSyn-SAA. - Plasma analytes measured: **P-tau217** (Roche Diagnostics), neurofilament light chain (**NfL**, Quanterix), glial fibrillary acidic protein (**GFAP**, Quanterix); in PD only, amyloid-beta 40 and 42 (C2N Diagnostics). - Median biomarker values (pg/mL) reported: P-tau217 — HC 0.14 [0.06–0.75], PD 0.15 [0.06–0.90]; NfL — HC 10.6 [3.13–49.85], PD 12.26 [3.77–62.67]; GFAP — HC 66.56 [19.75–403.48], PD 87.19 [14.55–531.82]; PD Aβ40 391.32 [209.95–538.38], Aβ42 42.74 [27.75–68.55]. - No biomarker concentrations differed between HC and PD at baseline. - In PD, biomarker levels correlated with age. - Higher baseline **P-tau217** and **NfL** in PD were associated with greater hazards of worse cognitive and balance outcomes during follow-up. - **P-tau217**, **NfL**, and **GFAP** levels were associated with longitudinal change in cognitive scores. - Authors reported follow-up up to 11 years and used models controlling for age, sex, and baseline outcome variables. - The source did not report specific statistical effect sizes, p-values, or detailed model parameters in the abstract; such details would be in the full manuscript or supplement.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=rBgkUlGzZ8z6eNd5Qat2tS8hRjseITa2grcxlqbX1Ro-1795203085.8645637-1.2.1.1-jtN7Vs5bURx2M.DVQUT992rc_nAgSCE2QXwE_P4vSHPrnvGCt3laT4m4_Zq6gRRc) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.11.18.26368420v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Plasma neurodegeneration biomarkers and clinical progression in early sporadic Parkinson's disease [ View ORCID Profile](http://orcid.org/0000-0003-0766-1496)Thomas F Tropea, David G Coughlin, Sarah M. Brooker, Krittika Chatterjee, Noah S. Johnson, Micah Marshall, Anuprita Nair, Javier E. Flores, David-Erick Lafontant, Christopher S Coffey, Kristopher M. Kirmess, Tim West, Philip B. Verghese, Kristen A. Russ, Amanda Morris, Ming Lu, Leonardo Iaccarino, Patricia Aldea-Stevenson, Matthew Flitter, Rose Beck, Samantha Hutten, Lana M. Chahine, Daniel Weintraub, Tatiana Foroud, Tanya Simuni, Kenneth Marek, Kalpana Merchant, The Parkinson's Precision Medicine Initiative doi: https://doi.org/10.64898/2026.11.18.26368420 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Thomas F Tropea 1 Institute for Neurodegenerative Disorders; New Haven, CT, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Thomas%2BF%2BTropea%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Tropea%20TF&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AThomas%2BF%2BTropea%2B) * [ORCID record for Thomas F Tropea](http://orcid.org/0000-0003-0766-1496 "Open in new tab") * For correspondence: thomas.tropea@pennmedicine.upenn.edu David G Coughlin 2 Department of Neurosciences, University of California San Diego; San Diego, CA, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=David%2BG%2BCoughlin%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Coughlin%20DG&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADavid%2BG%2BCoughlin%2B) Sarah M. Brooker 3 Department of Neurology, Northwestern University, Chicago; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sarah%2BM.%2BBrooker%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Brooker%20SM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASarah%2BM.%2BBrooker%2B) Krittika Chatterjee 4 Department of Biostatistics, University of Iowa, Iowa City, IA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Krittika%2BChatterjee%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Chatterjee%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKrittika%2BChatterjee%2B) Noah S. Johnson 4 Department of Biostatistics, University of Iowa, Iowa City, IA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Noah%2BS.%2BJohnson%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Johnson%20NS&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANoah%2BS.%2BJohnson%2B) Micah Marshall 4 Department of Biostatistics, University of Iowa, Iowa City, IA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Micah%2BMarshall%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Marshall%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMicah%2BMarshall%2B) Anuprita Nair 4 Department of Biostatistics, University of Iowa, Iowa City, IA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Anuprita%2BNair%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Nair%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAnuprita%2BNair%2B) Javier E. Flores 4 Department of Biostatistics, University of Iowa, Iowa City, IA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Javier%2BE.%2BFlores%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Flores%20JE&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJavier%2BE.%2BFlores%2B) David-Erick Lafontant 4 Department of Biostatistics, University of Iowa, Iowa City, IA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=David-Erick%2BLafontant%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Lafontant%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADavid-Erick%2BLafontant%2B) Christopher S Coffey 4 Department of Biostatistics, University of Iowa, Iowa City, IA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Christopher%2BS%2BCoffey%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Coffey%20CS&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AChristopher%2BS%2BCoffey%2B) Kristopher M. Kirmess 5 C2N Diagnostics, LLC; St. Louis, MO, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kristopher%2BM.%2BKirmess%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kirmess%20KM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKristopher%2BM.%2BKirmess%2B) Tim West 5 C2N Diagnostics, LLC; St. Louis, MO, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Tim%2BWest%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=West%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATim%2BWest%2B) Philip B. Verghese 5 C2N Diagnostics, LLC; St. Louis, MO, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Philip%2BB.%2BVerghese%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Verghese%20PB&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APhilip%2BB.%2BVerghese%2B) Kristen A. Russ 6 Department of Medical and Molecular Genetics, Indiana University; Indianapolis, IN, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kristen%2BA.%2BRuss%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Russ%20KA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKristen%2BA.%2BRuss%2B) Amanda Morris 7 Eli Lilly and Company; Indianapolis, IN, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Amanda%2BMorris%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Morris%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAmanda%2BMorris%2B) Ming Lu 7 Eli Lilly and Company; Indianapolis, IN, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ming%2BLu%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Lu%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMing%2BLu%2B) Leonardo Iaccarino 7 Eli Lilly and Company; Indianapolis, IN, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Leonardo%2BIaccarino%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Iaccarino%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALeonardo%2BIaccarino%2B) Patricia Aldea-Stevenson 7 Eli Lilly and Company; Indianapolis, IN, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Patricia%2BAldea-Stevenson%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Aldea-Stevenson%20P&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APatricia%2BAldea-Stevenson%2B) Matthew Flitter 7 Eli Lilly and Company; Indianapolis, IN, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Matthew%2BFlitter%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Flitter%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMatthew%2BFlitter%2B) Rose Beck 7 Eli Lilly and Company; Indianapolis, IN, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Rose%2BBeck%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Beck%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARose%2BBeck%2B) Samantha Hutten 8 The Michael J. Fox Foundation for Parkinsons Research; New York, New York, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Samantha%2BHutten%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hutten%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASamantha%2BHutten%2B) Lana M. Chahine 9 Department of Neurology, University of California San Franscisco, San Franscico PA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Lana%2BM.%2BChahine%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Chahine%20LM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALana%2BM.%2BChahine%2B) Daniel Weintraub 10 Department of Psychiatry, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Daniel%2BWeintraub%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Weintraub%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADaniel%2BWeintraub%2B) Tatiana Foroud 11 Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Tatiana%2BForoud%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Foroud%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATatiana%2BForoud%2B) Tanya Simuni 3 Department of Neurology, Northwestern University, Chicago; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Tanya%2BSimuni%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Simuni%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATanya%2BSimuni%2B) Kenneth Marek 1 Institute for Neurodegenerative Disorders; New Haven, CT, USA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kenneth%2BMarek%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Marek%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKenneth%2BMarek%2B) Kalpana Merchant 3 Department of Neurology, Northwestern University, Chicago; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kalpana%2BMerchant%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Merchant%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKalpana%2BMerchant%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.11.18.26368420v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1349848/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.11.18.26368420v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1349848/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.11.18.26368420v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1349848/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.11.18.26368420v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1349848/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.11.18.26368420v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1349848/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.11.18.26368420v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1349848/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Objectives: Plasma neurodegeneration biomarkers offer an opportunity to characterize Parkinson's disease (PD) biology. The objective of this study was to investigate such biomarkers in deeply-phenotyped participants in Parkinson's Precision Medicine Initiative (PPMI). Methods: Baseline plasma samples from early (<2 years since diagnosis) sporadic PD participants with a positive CSF alpha-synuclein seed amplification assay (aSyn-SAA) and healthy controls (HC) with a negative aSyn-SAA test were utilized. Plasma P-tau217 (Roche Diagnostics), neurofilament light chain (NfL, Quanterix), glial fibrillary acidic protein (GFAP, Quanterix), and (PD only) amyloid-beta (Aβ) levels (40 and 42, C2N Diagnostics) were measured. Clinical features at baseline and over up to 11 years were compared across biomarker tertiles in models controlling for age, sex, and baseline outcome variable. Results: The cohort was 97 HC and 523 PD and participants. Median [IQR] biomarker values (pg/mL) for HC and PD were P-tau217: 0.14 [0.06 -0.75], 0.15 [0.06 -0.90]; NfL: 10.6 [3.13 -49.85], 12.26 [3.77-62.67]; GFAP: 66.56 [19.75 -403.48], 87.19 [14.55 -531.82]; and in PD Aβ40: 391.32 [209.95 -538.38]; Aβ42: 42.74[27.75 -68.55]. No biomarkers differed between HC and PD. In PD, biomarkers were associated with age. In PD only, higher baseline levels of P-tau217 and NfL were associated with greater hazards of a worse cognitive and balance outcome. P-tau217, NfL, and GFAP levels were associated with change in cognitive score over time. Interpretation: Plasma P-tau217, NfL and GFAP levels in early, sporadic PD with confirmed synucleinopathy predict future cognitive and functional impairment, and these findings can inform clinical research design and clinical care. ### Competing Interest Statement Potential Conflicts of Interest: TFT has nothing to declare. DGC has nothing to declare. SMB has nothing to declare. KC has nothing to declare. NSJ has nothing to declare. MM has nothing to declare. AN has nothing to declare. JEF has nothing to declare. D-EL has nothing to declare. CSC has nothing to declare. KK is an employee of C2N Diagnostics, LLC and is compensated by C2N. TW is an employee of C2N Diagnostics, LLC and is compensated by C2N. PV is an employee of C2N Diagnostics, LLC and is compensated by C2N. KAR has nothing to declare. AM is a full-time employee and shareholder of Eli Lilly and Company. ML is a full-time employee and shareholder of Eli Lilly and Company. LI is a full-time employee and shareholder of Eli Lilly and Company. PA-S is a full-time employee and shareholder of Eli Lilly and Company. MF is a full-time employee and shareholder of Eli Lilly and Company. RB is a full-time employee and shareholder of Eli Lilly and Company. SH has nothing to declare. LMC has nothing to declare. DW has nothing to declare. TF has nothing to declare. TS has nothing to declare. KMa has nothing to declare. KMe has
## Related Clinical Research

- [Mechanical constraints and optic nerve head size explain interspecies lamina cribrosa differences](https://medichelpline.com/clinical-feed/biorxiv-2-interspecies-differences-in-lamina-cribrosa-fiber-composition-and-architecture.md)
- [Cell-type X-chromosome Regulation Identifies Sex-Biased Genes Linked to Neurodegeneration](https://medichelpline.com/clinical-feed/medrxiv-16-brain-cell-type-specific-x-chromosome-gene-regulation-reveals-sex-biased.md)
- [Neural competition links right-hemisphere deficit to speech gains in congenital amusia](https://medichelpline.com/clinical-feed/biorxiv-3-neural-competition-predicts-speech-production-advantages-in-congenital-amusia.md)
- [Bilateral Carotid Artery Stenosis Linked to Slightly Higher Restless Legs Syndrome Risk](https://medichelpline.com/clinical-feed/medrxiv-23-carotid-artery-stenosis-is-associated-with-restless-legs-syndrome-in-the.md)
- [U.S. POINTER: Structured lifestyle program slows brain aging and cardiometabolic risk over 24 mont](https://medichelpline.com/clinical-feed/medical-news-today-0-combining-physical-mental-and-social-habits-slows-brain-aging-in-2-year-trial.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.